Additionally, emerging pharmacological interventions, such as GLP-1 receptor agonists, SGLT1/2 inhibitors, and DPP-4 inhibitors, offer promise not only for diabetes management but also for preventing cardiac remodeling and warrant further investigation for integration into perioperative care. This evidence concerns the gene DPP4 and diabetes mellitus.